Table 3.

Primary Outcome: Composite Cardiovascular Events

Covariates	All Patients
	(Cases, n = 231,967; Controls, n = 2,319,670)
	Odds Ratio	95% CI		P value
Demographics
Age Group (years)
18–34 (reference)
35–44	2.59	2.49	2.70	<0.001
45–54	5.69	5.49	5.89	<0.001
55–64	9.72	9.39	10.05	<0.001
65–74	12.35	11.94	12.79	<0.001
75+	20.04	19.35	20.77	<0.001
Sex
Male	1.18	1.16	1.20	<0.001
Race
White (reference)
Black or African American	1.08	1.07	1.10	<0.001
Other	1.13	1.12	1.15	<0.001
Predefined risk factors
Diabetes	1.33	1.32	1.35	<0.001
Hypertension	1.57	1.55	1.59	<0.001
Dyslipidemia	0.91	0.90	0.92	<0.001
History of Myocardial Infarction	2.07	2.01	2.13	<0.001
Arthritis or Spondylitis	1.22	1.19	1.26	<0.001
Peripheral Arterial Disease	1.23	1.21	1.26	<0.001
Chronic Kidney Disease	1.42	1.39	1.44	<0.001
Atherothrombotic Disease	1.55	1.51	1.60	<0.001
History of Tobacco Use (Dx Only)	1.37	1.35	1.39	<0.001
Cerebrovascular Disease	5.04	4.95	5.13	<0.001
Coronary Artery Disease	1.77	1.75	1.80	<0.001
Cardiomyopathy	2.70	2.63	2.78	<0.001
Aspirin Use	1.71	1.69	1.73	<0.001
Other Anticoagulant Use	2.58	2.53	2.62	<0.001
Obstructive Sleep Apnea	1.06	1.05	1.07	<0.001
Liver Dysfunction	1.40	1.36	1.44	<0.001
COPD	1.61	1.59	1.63	<0.001
Prescription drug information
By selectivity
COX 1	1.03	1.00	1.05	0.0291
COX 2	1.09	1.06	1.11	<0.001
Non-Selective	1.08	1.05	1.10	<0.001
By dose category
Low/Medium Dose	1.06	1.02	1.10	0.0014
High Dose	1.02	0.98	1.05	0.3619
Time since initial exposure (days)
No Exposure (reference)
LEQ 30	8.97	8.58	9.37	<0.001
31–90	9.54	9.15	9.96	<0.001
91–180	8.69	8.33	9.07	<0.001
181–365	8.02	7.69	8.37	<0.001
366–730	7.14	6.85	7.45	<0.001
731+	5.80	5.55	6.06	<0.001